Question 1

What is Leucovorin used for?

Accepted Answer

Leucovorin is a Folate Analog medication tracked in Medicare Part D.

Question 2

Is there a generic for Leucovorin?

Accepted Answer

Yes. 45 ANDAs filed at FDA, 11 generic manufacturers currently shipping.

Question 3

How much does my plan pay for Leucovorin?

Accepted Answer

Across 329 Part D plans, Leucovorin averages $1.26/unit (NADAC). Lowest available: $0.431/unit. Highest in distribution: $2.36/unit.

Question 4

Is Leucovorin on the FDA shortage list?

Accepted Answer

No. Leucovorin is not currently on the FDA Drug Shortage Database.

Question 5

What drug class is Leucovorin in?

Accepted Answer

Leucovorin is in the Folate Analog class. See related drugs in this class at /class/folate-analog.

Question 6

What is the brand name for Leucovorin?

Accepted Answer

Leucovorin is sold under the brand name VYKOURA.

Question 7

Is VYKOURA the same as Leucovorin?

Accepted Answer

Yes. VYKOURA is a brand name for Leucovorin. The generic version is identical in active ingredient, dose, and FDA-approved indications. Pricing differs substantially: generic Leucovorin typically prices well below brand VYKOURA.

Question 8

How much does Medicare spend on Leucovorin per year?

Accepted Answer

Medicare Part D spent $7.4M on Leucovorin in CY2024, across 158K prescriptions and 52K unique beneficiaries.

Question 9

Why is there a spread between low and average NADAC for Leucovorin?

Accepted Answer

The 3× spread between lowest NADAC ($0.431/unit on generic NDCs) and average NADAC ($1.26/unit across all NDCs) reflects that brand-tier NDCs are still in distribution at higher prices. Most plans haven't migrated utilization toward the generic NDCs yet. For plans, this is the structural source of within-molecule savings opportunity.

Question 10

What can I switch to instead of Leucovorin?

Accepted Answer

Same-class alternatives include: Levoleucovorin. Whether substitution is clinically appropriate depends on patient indication, dose schedule, and contraindications — that is a P&T committee decision. The federal data shows cost and competition; clinical equivalence is not asserted here.

Question 11

Why isn't Leucovorin cheaper if there's no PA friction?

Accepted Answer

Leucovorin has 11 generic manufacturers and zero prior-authorization barriers across 329 Part D plans. Why it isn't already cheaper on most plans: tier placement and PBM contract structure, not clinical or supply factors. Moving the molecule to a lower formulary tier captures the savings — see leak report for sizing.

Question 12

When did the most recent Leucovorin generic get approved?

Accepted Answer

The most recent ANDA approval for Leucovorin is AVYXA HOLDINGS LLC (ANDANDA220406, approved 2026-02-03).

Question 13

When was Leucovorin first FDA approved?

Accepted Answer

Leucovorin received its first FDA approval on 1987-09-14.

Leucovorin (VYKOURA)

$7.4M in CY2024 Part D spend158K claims · 52K beneficiaries · 329 plans surveyed

Questions a plan sponsor actually asks.

Related questions.

Same class. Different math.

Sources · every number above traces back.